Colorectal Cancer

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

Study Found Worse Survival for Patients with Familial Colorectal Cancer Type X

By

In patients who developed CRC, those who had familial CRC type X were found to have worse survival outcomes than those who had Lynch syndrome.

<i>BRCA1</i> Mutation Observed to Confer Heightened Risk of Colorectal Cancer

BRCA1 Mutation Observed to Confer Heightened Risk of Colorectal Cancer

By

A systematic review and meta-analysis determined that carriers for a mutation to BRCA1, but not BRCA2, have an increased risk of colorectal cancer.

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

Bevacizumab Biosimilar Deemed Bioequivalent to Reference Drug in Metastatic CRC

By

Both the reference product and its biosimilar confer to same benefit, according to research results.

Native Puerto Ricans Are at Increased Risk for Certain Cancers

Native Puerto Ricans Are at Increased Risk for Certain Cancers

By

Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes

By

Stool burden can be a particularly challenging aspect of colonoscopies, making potentially cancerous lesions easier to miss.

Tailoring fecal immunochemical tests positivity thresholds by age and sex may help to optimize colorectal cancer screening

FIT directly measure human hemoglobin concentrations in the stool commonly and are commonly used for colorectal cancer screening.

Fruquintinib increases overall survival in metastatic colorectal carcinoma

Biological agents that target VEGF or EGFR are often used in conjunction with other chemotherapies to treat metastatic colorectal carcinoma (CRC).

Aspirin and Colorectal Cancer

Aspirin and Colorectal Cancer

By

Studies attempting to link ASA to a reduction in the risk of CRC have had mixed results.

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in <I>BRAF<sup>V600E</sup></i>-Mutant CRC

Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

By

Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen a breakthrough therapy designation.

Vitamin D and Colorectal Cancer

Vitamin D and Colorectal Cancer

By

The vitamin D response element plays a direct role in regulating gene expression, a potential mechanism to explain how vitamin D is involved with malignancy.

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

By

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Real-World Study Reports PFS and OS in Metastatic CRC

Real-World Study Reports PFS and OS in Metastatic CRC

By

A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

By

CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

By

Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

By

In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

By

The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

By

Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.

Liquid Biopsy Test Accurately Detects <i>RAS</i> Mutations in Metastatic Colorectal Cancer

Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer

By

The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.

Patients with advanced adenomas are at increased risk of developing colorectal cancer

In this randomized screening trial, patients with advanced adenomas detected by flex sigmoidoscopy (FSG) were at significantly increased risk of CRC compared to those with no adenomas.

BEACON CRC Safety Lead-in Study suggests safety and efficacy of triplet combination therapy for treatment of metastatic colorectal cancer

Preliminary analysis of the Safety Lead-in Study for the BEACON CRC reveals that the triplet combination is generally well tolerated and has promising clinical activity with an overall response rate of 41%.

iPad app that allows patients to order tests doubles colon cancer screening rates in study

The authors of this study at Wake Forest School of Medicine aimed to evaluate whether utilizing an iPad app as a digital health intervention could result in higher screening rates for CRC.

Colonoscopy significantly reduces mortality from colorectal cancer in Veterans Affairs study

Colorectal cancer (CRC) screening serves as a critical element of CRC prevention and management. To date, colonoscopy remains the gold standard with respect to CRC screening in the United States.

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

Obstructing Colorectal Cancer: Presentation and Stenting — In the Clinic

By

Colonic stenting can be used as a temporizing measure to help bridge the patient to surgery for optimal timing.

Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC

Modified XELIRI Yields Similar Outcomes to FOLFIRI in Metastatic CRC

By

The purpose of this trial was to determine the efficacy and safety of mXELIRI as a second-line therapy for CRC in an Asian population.

High Nut Intake Improves Survival Among Patients With Colon Cancer

High Nut Intake Improves Survival Among Patients With Colon Cancer

By

Nut intake is associated with a reduced risk of type 2 diabetes and insulin resistance.

mFOLFOXIRI Plus Cetuximab May Improve Resection Rate in Metastatic Colorectal Cancer

mFOLFOXIRI Plus Cetuximab May Improve Resection Rate in Metastatic Colorectal Cancer

By

Researchers randomly assigned 143 patients to receive cetuximab plus mFOLFOXIRI followed by cetuximab or bevacizumab maintenance.

Novel pSTAT3 Inhibitor Fails To Prolong OS in Advanced Colorectal Cancer

Novel pSTAT3 Inhibitor Fails To Prolong OS in Advanced Colorectal Cancer

By

Preclinical studies demonstrated that napabucasin — a first-in-class cancer stemness inhibitor that blocks STAT3 — may prevent self-renewal and induce cancer stem cell death.

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

By

Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

By

Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs